Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 675-684

  Stewart, David J ^a   Nunez, Maria I ^b   Behrens, Carmen ^b   Liu, Diane ^b   Lin, Yan Heather ^b   Lee, J Jack ^b   Roth, Jack ^b   Heymach, John ^b   Swisher, Stephen G ^b   Hong, Waun Ki ^b   Wistuba, Ignacio Ivan ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carbonic anhydrase IX; Non small cell lung cancer

Indexed keywords

CARBONATE DEHYDRATASE IX; CARRIER PROTEIN; CELL NUCLEUS DNA; COPPER TRANSPORTER 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKINE RECEPTOR; DECOY RECEPTOR 2; DNA METHYLTRANSFERASE 1; ENHANCER OF SPLIT AND HAIRY RELATED PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PHOSPHOPROTEIN; PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR NECROSIS; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CHEMISTRY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; SECONDARY; SURVIVAL RATE; TIME; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84899474099     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000148     Document Type: Article

References (74)

1. Jemal A Bray F Center MM Ferlay J Ward E Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R Naishadham D Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012;62:10-29.
3. Chansky K Sculier JP Crowley JJ Giroux D Van Meerbeeck J Goldstraw P; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801.
4. Stewart DJ Kurzrock R. Fool's gold lost treasures and the randomized clinical trial. BMC Cancer 2013;13:193.
5. Kononen J Bubendorf L Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
6. Stewart DJ Behrens C Roth J Wistuba II. Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer 2011;71:217-223.
7. Malentacchi F Simi L Nannelli C et al. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer 2009;64:271-276.
8. Simi L Venturini G Malentacchi F et al. Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer 2006;52:59-66.
9. Zhao X Liu X Guo W Li X. [Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression]. Zhongguo Fei Ai Za Zhi 2010;13:861-866.
10. Kim SJ Rabbani ZN Vollmer RT et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 2004;10:7925-7933.
11. Swinson DE Jones JL Richardson D et al. Carbonic anhydrase IX expression a novel surrogate marker of tumor hypoxia is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21:473-482.
12. Vermylen P Roufosse C Burny A et al. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J 1999;14:806-811.
13. Kon-no H Ishii G Nagai K et al. Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer 2006;54:409-418.
14. An Q Liu Y Huang J. [Comparison of tumor suppressor gene deletion between squamous cell carcinoma and adenocarcinoma lung cancer in Chinese]. Zhonghua Zhong Liu Za Zhi 2001;23:470-472.
15. Ho WL Chang JW Tseng RC et al. Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect Prev 2002;26:343-349.
16. Dmitriev AA Kashuba VI Haraldson K et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 2012;7:502-513.
17. Pinato DJ Ramachandran R Toussi ST et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer 2013;108:429-437.
18. Wykoff CC Beasley NJ Watson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-7083.
19. Sandlund J Oosterwijk E Grankvist K Oosterwijk-Wakka J Ljungberg B Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007;100:556-560.
20. Takacova M Bartosova M Skvarkova L et al. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett 2013;5:191-197.
21. Choschzick M Oosterwijk E Müller V et al. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 2011;459:193-200.
22. van der Groep P Bouter A Menko FH van der Wall E van Diest PJ. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 2008;111:475-480.
23. Chia SK Wykoff CC Watson PH et al. Prognostic significance of a novel hypoxia-regulated marker carbonic anhydrase IX in invasive breast carcinoma. J Clin Oncol 2001;19:3660-3668.
24. Kaya AO Gunel N Benekli M et al. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. J BUON 2012;17:663-668.
25. Choi J Jung WH Koo JS. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology 2013;80:41-52.
26. Mees G Vangestel C Dierckx R Pauwels P Van Meerbeeck J Van de Wiele C. Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer. Cancer Biother Radiopharm 2010;25:149-154.
27. G ieling RG Williams KJ. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem 2013;21:1470-1476.
28. Proescholdt MA Merrill MJ Stoerr EM Lohmeier A Pohl F Brawanski A. Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol 2012;14:1357-1366.
29. Sørensen BS Hao J Overgaard J et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005;76:187-193.
30. Rafajová M Zatovicová M Kettmann R Pastorek J Pastoreková S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004;24:995-1004.
31. Beasley NJ Wykoff CC Watson PH et al. Carbonic anhydrase IX an endogenous hypoxia marker expression in head and neck squamous cell carcinoma and its relationship to hypoxia necrosis and microvessel density. Cancer Res 2001;61:5262-5267.
32. Mayer A Höckel M Vaupel P. Endogenous hypoxia markers: case not proven! Adv Exp Med Biol 2008;614:127-136.
33. Le QT Chen E Salim A et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006;12:1507-1514.
34. G oethals L Debucquoy A Perneel C et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 2006;65:246-254.
35. Ihnatko R Kubes M Takacova M et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006;29:1025-1033.
36. Andersen S Eilertsen M Donnem T et al. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 2011;72:294-302.
37. Ilie M Mazure NM Hofman V et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010;102:1627-1635.
38. Swinson DE Cox G O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer 2004;91:1301-1307.
39. Kim SJ Rabbani ZN Dewhirst MW et al. Expression of HIF-1alpha CA IX VEGF and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005;49:325-335.
40. Skrzypski M Jassem E Taron M et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008;14:4794-4799.
41. Boeuf S Bové e JV Lehner B Hogendoorn PC Richter W. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology 2010;56:641-651.
42. Maseide K Kandel RA Bell RS et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004;10:4464-4471.
43. Korkolopoulou P Perdiki M Thymara I et al. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 2007;38:629-638.
44. Dungwa JV Hunt LP Ramani P. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol 2012;43:1651-1660.
45. Klatte T Pantuck AJ Said JW et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009;15:1162-1169.
46. Trastour C Benizri E Ettore F et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007;120:1451-1458.
47. Brennan DJ Jirstrom K Kronblad A et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006;12:6421-6431.
48. Eckert AW Lautner MH Schütze A et al. Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 2010;39:313-317.
49. Hui EP Chan AT Pezzella F et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha carbonic anhydrase IX and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-2604.
50. Liao SY Darcy KM Randall LM et al. Prognostic relevance of carbonic anhydrase-IX in high-risk early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:452-458.
51. Korkeila E Sundström J Pyrhönen S Syrjänen K. Main effects and interactions of carbonic anhydrase IX hypoxia-inducible factor-1 ezrin and glucose transporter-1 in multivariate analysis for disease outcome in rectal cancer. Anticancer Res 2012;32:3299-3303.
52. Jensen R Lee J. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia vascularity and proliferation. Neurosurgery 2012;71:146-156.
53. Chang DT Chapman CH Norton JA et al. Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010;116:5179-5187.
54. Weber DC Tille JC Combescure C et al. The prognostic value of expression of HIF1 EGFR and VEGF-A in localized prostate cancer for intermediate-and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol 2012;7:66.
55. Bui MH Visapaa H Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004;171(6 Pt 1):2461-2466.
56. Phuoc NB Ehara H Gotoh T et al. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep 2008;20:525-530.
57. Brockton NT Klimowicz AC Bose P et al. High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncol 2012;48:615-622.
58. Kwon JE Jung WH Koo JS. The expression of metabolism-related proteins in phyllodes tumors. Tumour Biol 2013;34:115-124.
59. Turner KJ Crew JP Wykoff CC et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 2002;86:1276-1282.
60. Vleugel MM Greijer AE Shvarts A et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005;58:172-177.
61. Juhász M Chen J Lendeckel U et al. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharmacol Ther 2003;18:837-846.
62. Hiraoka N Ino Y Sekine S et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 2010;103:1057-1065.
63. Furlan D Sahnane N Carnevali I et al. Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 2008;39:1483-1494.
64. Takacova M Holotnakova T Barathova M Pastorekova S Kopacek J Pastorek J. Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor Oncol Rep 2010;23:869-874.
65. Klatte T Seligson DB Riggs SB et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007;13:7388-7393.
66. Kuijper A van der Groep P van der Wall E van Diest PJ. Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res 2005;7:R808-R818.
67. Vleugel MM Shvarts D van der Wall E van Diest PJ. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum Pathol 2006;37:1085-1092.
68. Sobhanifar S Aquino-Parsons C Stanbridge EJ Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 2005;65:7259-7266.
69. Kopacek J Barathova M Dequiedt F et al. MAPK pathway contributes to density-and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim Biophys Acta 2005;1729:41-49.
70. Nakamura J Kitajima Y Kai K et al. Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer. Am J Pathol 2011;178:515-524.
71. Jubb AM Pham TQ Hanby AM et al. Expression of vascular endothelial growth factor hypoxia inducible factor 1alpha and carbonic anhydrase IX in human tumours. J Clin Pathol 2004;57:504-512.
72. Stillebroer AB Boerman OC Desar IM et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol 2013;64:478-485.
73. Muriel Ló pez C Esteban E Astudillo A et al. Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 2012;30:2443-2449.
74. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010;75:173-234.